|

NovoTTF Treatment Signatures in Glioblastoma Patients At Autopsy

RECRUITINGSponsored by Medical College of Wisconsin
Actively Recruiting
SponsorMedical College of Wisconsin
Started2017-06-01
Est. completion2026-05-31
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT03194971

Summary

This study will assess whole brain samples from glioblastoma patients at autopsy to determine the underlying pathological signatures of tumor treatment fields at autopsy.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Newly diagnosed glioblastoma, World Health Organization (WHO) grade IV, patients undergoing TTField therapy.
* Recurrent glioblastoma WHO grade IV, patients undergoing TTField therapy.

Exclusion Criteria:

* TTField compliance \< 75%.
* Any contraindication to Optune TTField treatment.
* Initial brain tumor diagnosis \< WHO grade IV.
* Duration of TTField therapy \< 3 months.

Conditions2

CancerGlioblastoma

Locations1 site

Froedtert & the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
Peter LaViolette414-456-7490plaviole@mcw.edu

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.